Immunexpress Revolutionizes Sepsis Detection
with Rapid, Immune Response-Based Technology –
Immunexpress Revolutionizes Sepsis Detection with Rapid, Immune Response-Based Technology –
and Results in Just One Hour.
Breaking New Ground in Sepsis Diagnosis
Immunexpress pioneers technology that rapidly detects sepsis by analyzing the patient's immune response, marking a paradigm shift from traditional pathogen detection methods. Our mission is to develop diagnostic tools that empower clinicians and patients in the fight against this life-threatening disease.
11 Million Deaths Globally Every Year Among 49 Million Cases
About Sepsis
Sepsis is caused by a patient’s overwhelming immune response to an infection and, if undetected or left untreated, leads to tissue damage, organ failure, permanent disability and often death.
#1 Cause of Death in Hospitals
Sepsis is the leading cause of death in hospitals, claiming more lives than any other condition due to its rapid onset and difficulty in early detection.
#1 Cost for Hospitals
Sepsis is the most costly condition for hospitals, driving healthcare expenses due to extended patient stays and intensive treatment requirements.
Reduced Mortality and Costs
Early identification of sepsis leads to reduced mortality rates and lowers healthcare costs by enabling timely and effective treatment.
Sepsis is caused by a patient’s overwhelming immune response to an infection.
If undetected or left untreated, sepsis leads to tissue damage, organ failure, permanent disability and often death. Around the world physicians struggle to rapidly and reliably identify sepsis due to the lack of adequate diagnostic tools.
Our Technology
Traditional tests produce clinically actionable results in 24-48 hours for 20% of all patients tested. SeptiCyte® RAPID produces clinically actionable results in one hour for 100% of patients tested.
Our Partners
We have developed the fully automated SeptiCyte® RAPID cartridge, compatible with the Biocartis Idylla™ platform, enabling the quantification and analysis of gene expression from whole blood to diagnose sepsis in suspected patients. With this technology, we aim to improve clinical and economic outcomes for patients and to benefit all key healthcare stakeholders: medical professionals and payers.
